Your browser doesn't support javascript.
loading
Methylation in the p53 promoter in epithelial ovarian cancer
Chmelarova, M; Krepinska, E; Spacek, J; Laco, J; Beranek, M; Palicka, V.
Affiliation
  • Chmelarova, M; Charles University. Faculty Hospital Hradec Kralove. Institute of Clinical Biochemistry and Diagnostics. Czech Republic
  • Krepinska, E; Charles University. Faculty Hospital Hradec Kralove. Czech Republic
  • Spacek, J; Charles University. Faculty Hospital Hradec Kralove. Czech Republic
  • Laco, J; Charles University. Faculty Hospital Hradec Kralove. Czech Republic
  • Beranek, M; Charles University. Faculty Hospital Hradec Kralove. Institute of Clinical Biochemistry and Diagnostics. Czech Republic
  • Palicka, V; Charles University. Faculty Hospital Hradec Kralove. Institute of Clinical Biochemistry and Diagnostics. Czech Republic
Clin. transl. oncol. (Print) ; 15(2): 160-163, feb. 2013. tab, ilus
Article in English | IBECS | ID: ibc-127072
Responsible library: ES1.1
Localization: BNCS
ABSTRACT

OBJECTIVE:

Ovarian cancer is a leading cause of death from gynecologic tumors, however, the molecular and especially epigenetic events underlying this transformation are poorly understood. Promoter methylation status of tumor suppressor genes may be associated with transcriptional silencing and tumor progression. It has been shown that methylation of CpG dinucleotides located in the promoter region of p53 is associated with low expression levels of this gene. The aim of this study was to investigate promoter methylation of p53 gene in ovarian cancer by comparison with normal ovarian tissue.

METHODS:

To search for promoter methylation of p53 gene we used methylation-specific PCR (MSP) to compare the methylation status of 66 tissue samples of ovarian cancer with 37 control samples.

RESULTS:

In our study methylation specific PCR revealed p53 promoter methylation in 34 of 66 (51.5 %) of specimens with ovarian cancer.

CONCLUSION:

These results indicate that methylation in p53 promoter region may play an important role in carcinogenesis of ovarian cancer and could potentially be used in screening of ovarian cancer, and may have implications for future chemotherapy based on epigenetic changes (AU)
Subject(s)
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Endocrine System Diseases / Ovary Cancer Database: IBECS Main subject: Ovarian Neoplasms / Tumor Suppressor Protein p53 / Promoter Regions, Genetic / Neoplasms, Glandular and Epithelial / DNA Methylation Limits: Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2013 Document type: Article Institution/Affiliation country: Charles University/Czech Republic
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Endocrine System Diseases / Ovary Cancer Database: IBECS Main subject: Ovarian Neoplasms / Tumor Suppressor Protein p53 / Promoter Regions, Genetic / Neoplasms, Glandular and Epithelial / DNA Methylation Limits: Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2013 Document type: Article Institution/Affiliation country: Charles University/Czech Republic
...